Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
P/E ratio for Arcutis Biotherapeutics, Inc. (ARQT)
P/E ratio as of 2023: -0.85
According to Arcutis Biotherapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.85. At the end of 2022 the company had a P/E ratio of -2.54.
P/E ratio history for Arcutis Biotherapeutics, Inc. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.85 |
| 2022 | -2.54 |
| 2021 | -4.98 |
| 2020 | -7.40 |
| 2019 | -19.77 |
| 2018 | -41.03 |
| 2017 | -158.69 |